I often write about fatty liver disease, a problem that is gaining mainstream recognition as published earlier this year in Newsweek. It is easy to assume that this is a...
Read More
There was a big splash in the news recently about a study showing coffee drinking prevented cirrhosis. This seems to have struck a chord with people, and I’ve been getting...
Read More
Galectin Therapeutics is focused on a treatment for advanced fatty liver disease, or NASH (non-alcoholic steatohepatitis), which includes those patients with advanced scarring, or who are at the end stage...
Read More
By Peter G. Traber, M.D. on April 21, 2016 I suppose it’s natural to assume that only overweight people get fatty liver disease (and NASH), but one thing I have...
Read More
By Peter G. Traber, M.D. on March 24, 2016 You may have seen Newsweek’s recent article on the growing impact of NASH, NASH Is the 21st Century’s Looming Health Threat....
Read More
By Peter G. Traber, M.D. on February 22, 2016 Everyone has had the experience of having their blood pressure taken and knows the importance of a normal reading for good...
Read More
By Peter G. Traber, M.D. on February 11, 2016 I wrote recently about the need for non-invasive tests to replace liver biopsies in the evaluation of liver fibrosis due to...
Read More
By Peter G. Traber, M.D. on February 3, 2016 Are you one of the nearly 40% of Americans classified as obese or are you overweight and inexorably headed towards obesity? ...
Read More
By Peter G. Traber, M.D. on January 20, 2016 Several of my past CEO Perspectives have touched on the need for a non-invasive test in diagnosing and following treatment of fatty...
Read More
By Galectin Therapeutics. on January 7, 2016 The many accomplishments at Galectin Therapeutics during 2015 ranged from incremental progress touching every aspect of our business to significant advancements with GR-MD-02. Importantly,...
Read More